Akèy › Glomerulonefrit IGA
Etid klinik pou Glomerulonefrit IGA ap rekrite nan Etazini
18 etid pou Glomerulonefrit IGA ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX9 etid
- Denver, CO5 etid
- Orlando, FL5 etid
- Los Angeles, CA4 etid
- Sioux City, IA4 etid
- Cedar Rapids, IA3 etid
- Johns Creek, GA3 etid
- Boston, MA3 etid
- New York City, NY3 etid
- Philadelphia, PA3 etid
- Columbus, OH3 etid
Pa eta
- Colorado7 etid
- Florid10 etid
- Georgia5 etid
- Iowa3 etid
- Kalifòni8 etid
- Massachusetts3 etid
- Michigan4 etid
- Minnesota3 etid
- New York5 etid
- Ohio4 etid
- Pennsylvania3 etid
- South Dakota4 etid
- Tennessee3 etid
- Texas9 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06935357A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 25, 2026 · NCT07541287Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou Sep 21, 2026 · NCT07498335Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou Sep 9, 2026 · NCT06994845Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06989359Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 17, 2026 · NCT06858319A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 10, 2026 · NCT07146906A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Ap rekriteFaz 2
Laj 16 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT06419205Study of WAL0921 in Patients With Glomerular Kidney Diseases
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT06466135Study of Ravulizumab in Pediatric Participants With Primary IgAN
Ap rekriteFaz 3
Laj 2 a 18 · Tout sèks · Mizajou Jul 30, 2026 · NCT07024563Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Ap rekriteFaz 2
Laj 18 a 99 · Tout sèks · Mizajou Jul 29, 2026 · NCT06797518Atacicept in Multiple Glomerular Diseases
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06983028Study of BHV-1400 in IgA Nephropathy
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jun 23, 2026 · NCT07054684Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Ap rekriteFaz 2
Laj 1 a 17 · Tout sèks · Mizajou May 12, 2026 · NCT05003986Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 3, 2025 · NCT06676579A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2025 · NCT06952426Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Ap rekriteFaz 2
Laj 16 ak plis · Tout sèks · Mizajou Apr 6, 2025 · NCT06740526Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 4, 2025 · NCT01802034Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.